Literature DB >> 4005129

A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers.

S L Grainger, V A John, P A Shotton, S E Smith.   

Abstract

Plasma metoprolol concentrations and haemodynamic effects have been measured in six healthy male volunteers during once daily dosing with a 19/285 Oros system and twice daily dosing with 100 mg conventional tablets, on two separate occasions. Plasma drug concentrations throughout the day varied less with the Oros than with the conventional tablet regimen. Predosing concentrations were also higher with Oros but areas under the curve, after correcting for the differences in dose, were similar for the two preparations. Inhibition of exercise tachycardia was drug concentration dependent and was smoothly controlled through the day only with the Oros preparation. Predosing effects at steady-state were also greater for the Oros regimen. The decline in mean blood pressure, however, showed the same daily pattern for both regimens, and no significant differences were detected between Oros and conventional tablet treatments. The smoothness of the plasma profiles after Oros confirmed the controlled-release performance of the system in vivo and indicates its potential in the treatment of angina, cardiac arrhythmias and wherever it is important not to jeopardize steady selective beta-adrenoceptor blockade.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005129      PMCID: PMC1463773          DOI: 10.1111/j.1365-2125.1985.tb02769.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

3.  Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration.

Authors:  R D Aarons; A S Nies; J Gal; L R Hegstrand; P B Molinoff
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

4.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

5.  Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism.

Authors:  A J McLean; P J McNamara; P duSouich; M Gibaldi; D Lalka
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

6.  Mechanism of propranolol withdrawal phenomena.

Authors:  S Nattel; R E Rangno; G Van Loon
Journal:  Circulation       Date:  1979-06       Impact factor: 29.690

7.  Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.

Authors:  M J Kendall; D B Jack; K L Woods; S J Laugher; C P Quarterman; V A John
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

8.  A double-blind crossover comparative study of the efficacy of single daily doses of conventional and slow-release metoprolol.

Authors:  J G Nievel; C W Harvard
Journal:  Curr Med Res Opin       Date:  1981       Impact factor: 2.580

9.  Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.

Authors:  S Freestone; J H Silas; M S Lennard; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

  9 in total
  3 in total

Review 1.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

Review 2.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

3.  Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations.

Authors:  J Richard; J M Cardot; J Godbillon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.